nir178 (a2a antagonist) Search Results


nexera series  (Shimadzu Corporation)
99
Shimadzu Corporation nexera series
Nexera Series, supplied by Shimadzu Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nexera series/product/Shimadzu Corporation
Average 99 stars, based on 1 article reviews
nexera series - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
nir178  (Novartis)
90
Novartis nir178
Clinical trials (from NIH and EU registers) testing the potential use of purinergic targets in pancreatic and other cancers. Purpose of the studies varies from feasibility to safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity.
Nir178, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nir178/product/Novartis
Average 90 stars, based on 1 article reviews
nir178 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
pbf-509 (or nir-178)  (Palobiofarma)
90
Palobiofarma pbf-509 (or nir-178)
Clinical trials (from NIH and EU registers) testing the potential use of purinergic targets in pancreatic and other cancers. Purpose of the studies varies from feasibility to safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity.
Pbf 509 (Or Nir 178), supplied by Palobiofarma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pbf-509 (or nir-178)/product/Palobiofarma
Average 90 stars, based on 1 article reviews
pbf-509 (or nir-178) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti-cd73 ab nzv930  (Novartis)
90
Novartis anti-cd73 ab nzv930
Clinical trials (from NIH and EU registers) testing the potential use of purinergic targets in pancreatic and other cancers. Purpose of the studies varies from feasibility to safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity.
Anti Cd73 Ab Nzv930, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd73 ab nzv930/product/Novartis
Average 90 stars, based on 1 article reviews
anti-cd73 ab nzv930 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
pdr001 (anti-pd-1 ab)  (Novartis)
90
Novartis pdr001 (anti-pd-1 ab)
Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.
Pdr001 (Anti Pd 1 Ab), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdr001 (anti-pd-1 ab)/product/Novartis
Average 90 stars, based on 1 article reviews
pdr001 (anti-pd-1 ab) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Clinical trials (from NIH and EU registers) testing the potential use of purinergic targets in pancreatic and other cancers. Purpose of the studies varies from feasibility to safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity.

Journal: International Journal of Molecular Sciences

Article Title: Purinergic Signaling in Pancreas—From Physiology to Therapeutic Strategies in Pancreatic Cancer

doi: 10.3390/ijms21228781

Figure Lengend Snippet: Clinical trials (from NIH and EU registers) testing the potential use of purinergic targets in pancreatic and other cancers. Purpose of the studies varies from feasibility to safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity.

Article Snippet: A2A , NIR178 in (A2A antagonist) in combination with PDR001 (anti-PD-1 Ab) , Novartis Pharmaceuticals , Patients with solid tumors (including pancreatic cancer) and Non-Hodgkin Lymphoma , NCT03207867 , Phase II.

Techniques: Clinical Proteomics, Drug discovery, Immunopeptidomics, Activity Assay, Biomarker Discovery, Ointment

Clinical trials (from NIH and EU registers) testing the potential use of purinergic targets in pancreatic and other cancers. Purpose of the studies varies from feasibility to safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity.

Journal: International Journal of Molecular Sciences

Article Title: Purinergic Signaling in Pancreas—From Physiology to Therapeutic Strategies in Pancreatic Cancer

doi: 10.3390/ijms21228781

Figure Lengend Snippet: Clinical trials (from NIH and EU registers) testing the potential use of purinergic targets in pancreatic and other cancers. Purpose of the studies varies from feasibility to safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity.

Article Snippet: CD73 +/− A2A , NZV930 (anti-CD73 Ab) +/− PDR001 (anti-PD-1 Ab) +/− NIR178 (A2A antagonist) , Novartis Pharmaceuticals , Patients with advanced cancers including PDAC , NCT03549000 , Phase I/Ib.

Techniques: Clinical Proteomics, Drug discovery, Immunopeptidomics, Activity Assay, Biomarker Discovery, Ointment

Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.

Journal: Frontiers in Physiology

Article Title: Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases

doi: 10.3389/fphys.2022.849258

Figure Lengend Snippet: Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.

Article Snippet: CD73 +/− A2AAR , NZV930 (anti-CD73 Ab) +/− PDR001 (anti-PD-1 Ab) +/− NIR178 (A2A antagonist) , Patients with advanced solid tumors including PDAC , NCT03549000 , Phase I/Ib , Novartis Pharmaceuticals.

Techniques: Clinical Proteomics